Clinical Trial Update: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating RAMucirumab in combination with TAS-102 versus TAS-102 alone for chemotherapy-refractory metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED